Home / Health / Encouraging formula from real-world users of HIV-prevention pill

Encouraging formula from real-world users of HIV-prevention pill


(Reuters Health) – A tablet meant to forestall HIV infections in high-risk people appears to be working, according to dual new studies.

In one study, conducted in a San Francisco area, there were no new HIV infections among 657 people who took a daily tablet Truvada. In a second study, people in a UK holding Truvada had a revoke risk of being diagnosed with HIV.

Truvada, made by Gilead, is authorized in a U.S. for “pre-exposure prophylaxis” (PrEP) of HIV, a pathogen that causes AIDS. Truvada might revoke a risk of HIV infection by as most as 92 percent, according to a U.S. Centers for Disease Control and Prevention. The tablet doesn’t strengthen opposite other intimately transmitted infections (STIs), however.

While Truvada has worked good in rarely tranquil clinical trials comparing it to a placebo, some people were endangered about how it would perform in real-world settings.

The San Francisco study, published in Clinical Infectious Diseases, concerned 657 members of a Kaiser Permanente medical system, ages 20 to 68, who used Truvada between 2012 and 2015. The immeasurable infancy were happy and bisexual men.

During a study, participants had no new HIV infections.

Half of them did have new STIs, however.

The investigate can’t contend possibly a high rate of STIs is due to PrEP use. STI diagnoses might have left adult since patients on PrEP tend to make some-more doctors’ visits, permitting some-more opportunities for infections to be found.

Forty-one percent of 143 investigate participants reported a diminution in condom use. But Dr. Jonathan Volk, an spreading illness medicine during Kaiser Permanente San Francisco Medical Center and a study’s lead author, pronounced there might be reasonable explanations for this finding, such as people entering monogamous relationships.

Given a high rate of STIs and a series of participants who pronounced they didn’t use condoms, it’s expected that though a tablet “we would have seen some new HIV infections,” Volk said.

A second investigate of Truvada, published in The Lancet, found that happy organisation who started on PrEP had significantly fewer new HIV infections than happy organisation who had to wait a year for a pill.

There were one to dual new HIV infections per 100 people per year among those on PrEP, compared to about 9 new infections per 100 participants per year in a organisation with behind access.

“When we do a math, a rebate was an 86 percent decrease,” pronounced Dr. Kenneth Mayer, a founder, co-Chair and medical investigate executive of The Fenway Institute in Boston.

Also, two-thirds of those who took PrEP though were still diagnosed with HIV during a UK investigate were expected already putrescent when they started a study, pronounced Mayer, who co-wrote an editorial concomitant a study.

Once a drug was found to be so effective, a researchers in a UK stopped a investigate to give all participants PrEP.

In a San Francisco-area study, it’s unfit to truly know how many infections might have been prevented though comparing a information to a identical organisation of people not regulating PrEP, Volk said.

Based on estimates from clinical hearing data, as many as 35 new HIV infections might have been prevented among a PrEP users.

In a UK study, Mayer said, participants’ unsure passionate behaviors didn’t change after PrEP.

“The information contend that people don’t indispensably boost their unsure behaviors and they don’t diminution their risk in this kind of environment either,” he said.

Volk pronounced a subsequent step is to learn how to get PrEP to other high-risk populations, such as transgender women.

“I don’t consider PrEP is a sorcery bullet, though we know that it does work unequivocally well,” he said. “It’s good to know we have options.”

SOURCES: bit.ly/1M21Mb8 Clinical Infectious Diseases, online Sep 1, 2015, and bit.ly/1UIgEmL and bit.ly/1UIgICX The Lancet, online Sep 9, 2015.

Article source: http://www.reuters.com/article/2015/09/11/us-health-hiv-prep-idUSKCN0RB2JE20150911

Scroll To Top